Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Lenvatinib Continues to be Noninferior to Sorafenib in HCC, Updated Results Show
September 17th 2017According to updated phase III results presented at the 11th Annual International Liver Cancer Association Conference, first-line therapy with Lenvatinib in the frontline setting continued to be noninferior in overall survival and achieve significant improvements in progression-free survival, time to progression, and objective response rate versus sorafenib for patients with unresectable hepatocellular carcinoma
Read More
Direct Acting Antivirals Not Associated With Increased HCC Recurrence
September 16th 2017Direct acting antivirals, a novel, oral hepatitis C therapy, is associated with a high response rate. DAAs are used in most patients being treated for hepatitis C, including those with decompensated cirrhosis. However, this treatment has been replaced by interferon-based therapy for patients with hepatitis C.
Read More
Improved Responses Found With BLU-554 for Hepatocellular Carcinoma
September 16th 2017According to findings presented at the 11th Annual Conference on the International Liver Cancer Association in Seoul, South Korea, BLU-554 induced an overall response rate of 16% in patients with FGF 19 immunohistochemistry-positive hepatocellular carcinoma. BLU-554 is a potent and highly selective inhibitor of fibroblast growth factor receptor 4.
Read More
ABP-215, First Biosimilar for Cancer Treatment, Approved by FDA
September 15th 2017Today, ABP-215, a biosimilar for bevacizumab developed by Amgen and Allergan, received FDA approval for the treatment of several different cancer types, making it the first biosimilar approved for the treatment of cancer.
Read More
FDA Extends Decision Deadline on Trastuzumab Biosimilar MYL-1401O
September 1st 2017The decision deadline on a biologics license application (BLA) for MYL-1401O, a trastuzumab (Herceptin) biosimilar co-developed by Mylan and Biocon, has been extended by 3 months, the FDA has announced. Under the new timeframe, a final decision is expected on or before December 3, 2017.
Read More
Expert Speaks on Importance of Genetic Testing in GI Cancers
August 24th 2017Antonia R. Sepulveda, MD, PhD, discusses the importance and utility of genetic testing in GI cancers, as well as noteworthy developments in microsatellite instability, <em>BRAF</em>, and <em>KRAS </em>testing in colorectal cancer.
Read More
Exploring the Decreasing Incidence of Colon Cancer in Those Over the Age of 50
August 18th 2017Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine and New York-Presbyterian Hospital, discusses the decreasing incidence of colon cancer diagnosis in those over the age of 50.
Watch
Novel Bispecific Antibody Shows Promising Efficacy in Heavily Pretreated mCRC
August 18th 2017In patients with heavily-pretreated microsatellite stable metastatic colorectal cancer (mCRC), treatment with CEA-TCB, an investigational CEA/CD3 bispecific antibody, showed a favorable safety profile and promising efficacy, with enhanced efficacy when combined with the PD-L1 inhibitor atezolizumab.
Read More
Expert Discusses Evaluation of Surgical Intervention in Metastatic CRC
August 17th 2017Dominik P. Modest, MD, discusses a retrospective, central evaluation of the FIRE-3 study to determine surgical treatment options, which explored the number of patients with metastatic colorectal cancer who had resectable disease during systemic first-line therapy.
Read More
Nivolumab Approved by FDA for MSI-H or dMMR Colorectal Cancer
August 1st 2017Nivolumab (Opdivo) has been granted an accelerated approval by the FDA for the treatment of adult and pediatric patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Read More
Simeone Leads New NYU Pancreatic Cancer Center
August 1st 2017Diane M. Simeone, MD, is stepping up to lead the new Pancreatic Cancer Center at NYU Langone. She has been a member of NYU Langone since March 2017, and will continue in her role as associate director of translational research at the Perlmutter Cancer Center.
Read More
Lutathera Receives EMA Panel's Support for Approval for GEP-NETs
July 24th 2017Lutathera (lutetium [<sup>177</sup>Lu] oxodotreotide) has been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with unresectable or metastatic, progressive, well-differentiated (grade 1 and grade 2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Read More
Sun Named Division Director of Medical Oncology at University of Kansas School of Medicine
July 11th 2017Weijing Sun, MD, has been appointed the new Sprint Foundation Professor of Medical Oncology and the director of the Division of Medical Oncology at The University of Kansas School of Medicine and The University of Kansas Cancer Center.
Read More
Intra-Tumor Heterogeneity in Primary and Metastatic HCC
July 11th 2017David J. Pinato, MD, PhD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses an analysis of intra-tumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma (HCC).
Watch
Diaz Discusses the FDA Approval of Pembrolizumab for MSI-H Solid Tumors
July 10th 2017Luis A. Diaz Jr, MD, head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of pembrolizumab (Keytruda) for microsatellite instability-high (MSI-H) colorectal cancer and other tumor types.
Watch
SIRT Demonstrates Unanticipated Benefit in Colorectal Cancer Patients With Liver Metastasis
July 10th 2017A large analysis of data comparing selective internal radiotherapy (SIRT) plus chemotherapy to chemotherapy did not show expected improvements in survival, but an unanticipated benefit was observed with SIRT in patients with metastatic colorectal cancer.
Read More
Prognostic Markers for Aflibercept Efficacy in CRC Identified by Biomarker Analysis
July 10th 2017Overall survival was prolonged with treatment with ziv-aflibercept compared to placebo across subgroups of patients with metastatic colorectal cancer with wild-type and mutated <em>RAS, KRAS,</em> and <em>BRAF</em> genes.
Read More